These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. IgG replacement therapy, no size fits all. Bonilla FA Clin Immunol; 2011 May; 139(2):107-9. PubMed ID: 21420364 [No Abstract] [Full Text] [Related]
4. [Immunoglobulins and immune deficiency: methods of administration]. Suarez F Rev Med Interne; 2005 Oct; 26 Spec No 1():25-8. PubMed ID: 16475260 [No Abstract] [Full Text] [Related]
5. Immunoglobulin Replacement Therapy for Primary Immunodeficiency. Sriaroon P; Ballow M Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315 [TBL] [Abstract][Full Text] [Related]
6. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies. Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705 [TBL] [Abstract][Full Text] [Related]
7. Successful treatment of systemic lupus erythematosus with subcutaneous immunoglobulin. Brasileiro A; Fonseca Oliveira J; Pinheiro S; Paiva-Lopes MJ Lupus; 2016 May; 25(6):663-5. PubMed ID: 26846694 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Berger M; Rojavin M; Kiessling P; Zenker O Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644 [TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomics of immunoglobulins in primary immunodeficiency. Simoens S Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):375-86. PubMed ID: 19670998 [TBL] [Abstract][Full Text] [Related]
17. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children]. Pac M Pol Merkur Lekarski; 2011 Jun; 30(180):413-6. PubMed ID: 21751550 [TBL] [Abstract][Full Text] [Related]
18. Potential Anti-Tumor Activity of Intravenous and Subcutaneous Immunoglobulin. Danieli MG; Gelardi C; Pedini V; Gabrielli A Isr Med Assoc J; 2018 Dec; 20(12):782-783. PubMed ID: 30550011 [No Abstract] [Full Text] [Related]
19. Considerations for the optimal use of immunoglobulin. Navarro RP; Ballow M; Fenrick B; Pezalla EJ Am J Manag Care; 2012 Jun; 18(4 Suppl):S67-78. PubMed ID: 22774920 [TBL] [Abstract][Full Text] [Related]
20. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies. Dams ET; van der Meer JW Lancet; 1995 Apr; 345(8953):864. PubMed ID: 7898254 [No Abstract] [Full Text] [Related] [Next] [New Search]